I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists.
Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.
FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.
The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients
Published in: British Jounal of Cancer
Background: The aim of this study was to evaluate the effect on the number of performed biopsies and costs associated with implementing positron emission tomography (PET) and computed tomography (PET/CT) with 16 alpha-[F-18]fluoro-17 beta-oestradiol (FES) or 2-[F-18] fluoro-2-deoxy-D-glucose (FDG) as an upfront imaging test for diagnosing metastatic breast cancer (MBC) in comparison with the standard work-up in oestrogen receptor-positive women with symptoms. Methods: A published computer simulation model was adapted and validated. Three follow-up strategies were evaluated in a simulated cohort of women with primary breast cancer over...
R. G. Koleva-Kolarova,
M. J. W. Greuter,
M. van Kruchten,
K. M. Vermeulen,
T. Feenstra,
E. Buskens,
A. W. J. M. Glaudemans,
E. F. J. de Vries,
E. G. E. de Vries,
G. A. P. Hospers,
G. H. de Bock
IMPACT: op weg naar een gepersonaliseerde antikankerbehandeling met behulp van moleculaire beeldvorming. Drie lopende studies voor mamma-, colorectaal en niercelcarcinoom
E J van Helden, Suzanne van Es,
Frederike Bensch, E Boon, C W Menke-van der Houven van Oordt,
Carolina Schröder, C M L van Herpen,
Adrienne Brouwers,
Andor W.J.M. Glaudemans, O S Hoekstra, W.J.G. Oyen, W.T.A. van der Graaf, H M V Verheul,
E. G. E. de Vries
RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical study
Published in: Cancer Research
Gary Hattersley, Frank David, Alan W. Harris, Marcie Clarkin, Kate Banks, Greg Williams,
Andor Glaudemans,
Janine Doorduin, Michel J. B. Koole,
Erik de Vries, Rich Lyttle
